Advent Venture Partners LLP insider trades: Conatus Pharmaceuticals (CNAT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Advent Venture Partners LLP reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 30, 2013 | CNAT | ↑ Buy | 190,054 | $11.00 | $2.1M | Indirect | Aug 1, 2013 (2d) |
| Jul 30, 2013 | CNAT | ↓ Sell | 535 | $11.00 | $6K | Indirect | Aug 1, 2013 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Advent Venture Partners LLP's insider trades
Advent Venture Partners LLP is a 10% owner of Conatus Pharmaceuticals (CNAT). Since Jul 30, 2013, it has reported 1 open-market purchase worth $2.1M and 1 sale worth $6K on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (1 filing), option exercises (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CNAT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.